Biotech is one of the fastest-moving sectors in today's business news. New therapies for rare diseases, cell and gene treatments and next-generation vaccines move from lab benches to clinical trials faster than ever. What rarely makes the headlines is how international these trials have become, and how much language work sits behind every study.
A single late-stage trial can run in thirty countries, with patients, doctors and regulators all needing documents in their own language.
Why trials go global
Recruiting enough patients is one of the hardest parts of drug development. For rare diseases, there may be only a few hundred eligible patients worldwide. Sponsors therefore open trial sites across Europe, North America, Asia and beyond. Public registries such as ClinicalTrials.gov show how many studies now list sites on several continents.
Every new country adds regulatory submissions, ethics committee approvals and local paperwork. In Europe, the European Medicines Agency coordinates much of the process, but national authorities and hospitals still expect materials in their official languages.
The documents behind a trial
- Informed consent forms that patients must fully understand
- Patient diaries, questionnaires and instructions for use
- Investigator brochures and trial protocols
- Safety reports and adverse event narratives
- Labels for investigational products and packaging
Each of these has its own risks. A confusing consent form can undermine ethical approval. An inaccurate patient questionnaire can distort results. A mistranslated dosage instruction can put people in danger.
In clinical research, translation quality is part of patient safety.
From email chains to managed workflows
Many smaller biotech companies start with email and spreadsheets, sending files to agencies and tracking versions by hand. As programmes grow, this quickly becomes unmanageable. Protocol amendments trigger updates to dozens of translated documents, and teams struggle to know which version is current in which country.
Larger sponsors and contract research organisations increasingly use an enterprise translation management system to control this complexity. It stores approved terminology, reuses previously translated passages, routes documents through translation, review and linguistic validation, and keeps an audit trail that inspectors can review.
German science, English submissions
Germany remains a major biotech hub, from Berlin and Munich to Mainz and Heidelberg. Many research reports, preclinical studies and manufacturing documents are written in German, while global submissions and partner communication happen in English.
That makes german to english translation services with scientific expertise an important part of the pipeline. Translators must handle complex terminology, statistical language and regulatory phrasing without losing precision.
Trials in Eastern Europe and Central Asia
Some sponsors run trial sites in countries of the Caucasus and Central Asia, where hospitals and patients often use Russian alongside national languages. Consent forms, patient materials and investigator communication may require english to russian translation, carefully adapted to local medical terminology and reading levels.
Linguistic validation adds another step. For patient questionnaires, translators produce two independent versions, reconcile them, back-translate into English and test the result with real patients. The goal is to make sure a question means the same thing in every language.
AI and machine translation in life sciences
Machine translation is attracting attention in biotech, especially for large volumes of internal documents and literature reviews. Used carefully, with expert post-editing, it can speed up work. For patient-facing materials and regulatory submissions, however, most sponsors still insist on full human translation and review. Regulators expect accountability, and patients deserve clarity.
Decentralised trials add new content
Many studies now include remote elements: patients report symptoms through apps, attend video visits with study nurses and receive medication at home. Each digital tool brings its own interface text, notifications and help screens, all of which must be translated and validated. A reminder that sounds friendly in English may feel intrusive or confusing in Japanese or Polish. Sponsors increasingly test these apps with local patients before launch, adding another layer of language work to already busy timelines.
Real-world evidence and publications
After approval, the flow of multilingual content continues. Post-marketing safety reports arrive in many languages, scientific publications need summaries for different audiences, and patient information leaflets must be updated whenever new data emerges. Companies that already have organised terminology and workflows handle these updates far more smoothly than those starting from scratch.
Why investors should care
Translation rarely appears in investor presentations, but delays in document preparation can push back trial starts and approvals. For a young biotech burning cash, a few months can matter. Companies that build reliable multilingual processes early reduce that risk and look more credible to partners and acquirers.
What the best teams do
- Build a controlled terminology base for each product early.
- Plan translation into trial timelines rather than treating it as an afterthought.
- Use specialised life science translators and reviewers.
- Keep version control and audit trails for every language.
- Involve local site staff in reviewing patient-facing materials.
Looking ahead
As more therapies target small patient populations spread across many countries, the language challenge will only grow. Biotech companies that treat multilingual communication as a core capability, not an administrative chore, will be better placed to run trials efficiently and bring new treatments to patients faster.